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ABSTRACT
Fracture risk is determined by bone strength and the risk of falls. The relationship between serum sex steroids and bone strength
parameters in men is well known, whereas the predictive value of sex steroids for falls is less studied. The aim of this study was to
assess the associations between serum testosterone (T) and estradiol (E2) and the likelihood of falls. Older men (aged 65 years)
from the United States (n¼ 1919), Sweden (n¼ 2495), and Hong Kong (n¼ 1469) participating in the Osteoporotic Fractures in Men
Study had baseline T and E2 analyzed by mass spectrometry. Bioavailable (Bio) levels were calculated using mass action equations.
Incident falls were ascertained every 4months during amean follow-up of 5.7 years. Associations between sex steroids and falls were
estimated by generalized estimating equations. Fall rate was highest in the US and lowest in Hong Kong (US 0.50, Sweden 0.31, Hong
Kong 0.12 fall reports/person/year). In the combined cohort of 5883 men, total T (odds ratio [OR] per SD increase¼ 0.88, 95%
confidence interval [CI] 0.86–0.91) and BioT (OR¼ 0.86, 95% CI 0.83–0.88) were associated with incident falls in models adjusted for
age and prevalent falls. These associations were only slightly attenuated after simultaneous adjustment for physical performance
variables (total T: OR¼ 0.94, 95% CI 0.91–0.96; BioT: OR¼ 0.91, 95% CI 0.89–0.94). E2, BioE2, and sex hormone-binding globulin
(SHBG) were not significantly associated with falls. Analyses in the individual cohorts showed that both total T and BioT were
associated with falls in MrOS US and Sweden. No association was found in MrOS Hong Kong, and this may be attributable to
environmental factors rather than ethnic differences because total T and BioT predicted falls in MrOS US Asians. In conclusion, low
total T and BioT levels, but not E2 or SHBG, are associated with increased falls in older men. © 2017 The Authors. Journal of Bone and
Mineral Research Published by Wiley Periodicals, Inc.
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Introduction
Fracture risk is determined by both bone strength and the riskof falls. Many studies have investigated the relationship
between serum sex steroids and bone strength parameters in
men, revealing the importance of estradiol (E2) for trabecular
and cortical bone properties.(1) In contrast, epidemiological
evidence supporting a role of sex steroids for fall risk in men is
limited and inconclusive.
Falls are a major public health concern in the aging
population.(2) More than one-third of community-dwelling
adults aged 75 years or older experience a fall each year. The
likelihood of falling increases with advancing age, and falls are
a leading source of injury and disability.(3) Serum levels of
testosterone (T), and especially bioavailable (Bio) T, decrease
with age in men, whereas serum E2 levels remain mostly
unchanged.(4,5) Several epidemiological studies support the
relation between this age-related decline in BioT levels and the
reduced muscle strength, loss of lean mass, and impaired
physical performance/mobility,(6–11) which in turn increase the
risk of falls.(12) T therapy in older men with low serum T levels
has been shown to increase physical ability and strength in
some studies,(13–15) whereas others, including the recent T
trial, described no or limited improvement in muscle strength
after T treatment.(16–19) Low T levels, expressed as apparent
free T concentrations, were associated with an increased
likelihood of falls in 792 older men in the MINOS study.(20) The
available data to date for incident fall risk are, however,
inconsistent. Men with BioT levels in the lowest quartile
(<175 ng/dL) had a 40% higher fall risk than those in the
highest quartile as shown in 2587 men during a 4-year follow-
up in the prospective MrOS US cohort, and this association
persisted after adjustment for physical performance.(21) Yet,
levels of total T were not associated with incident risk of falls in
623 older men in the LASA study.(7)
For all these studies, radioimmunoassay methods were used
to measure serum sex steroid levels. However, these methods
have been questioned for their limited accuracy and
specificity, especially at lower concentrations.(22–25) No data
are available documenting the association between serum sex
steroid levels measured by mass spectrometry (MS), consid-
ered the gold standard, and the risk of incident falls in men.
Therefore, this study prospectively investigated the relation
between serum levels of T and E2, assessed by MS, and sex
hormone-binding globulin (SHBG) and incident falls in a large
population of older men.
Materials and Methods
Study sample
The Osteoporotic Fractures in Men (MrOS) study is an
international multicenter, prospective study including older
men in the United States (n¼ 5994), Sweden (n¼ 3014), and
Hong Kong (n¼ 2000). In this study, associations between serum
sex steroids, SHBG, and incident falls were investigated in all
three cohorts separately and combined.
The MrOS US study enrolled 5994 community-dwelling
men at six academic medical centers.(26,27) Eligible partic-
ipants were at least 65 years old, could walk without
assistance, and had not had bilateral hip replacement
surgery. The MrOS US sample analyzed in the present study
consists of 70.3% non-Hispanic white men, 11.5% African
Americans, 8.8% Asians, and 9.4% other races and ethnicities.
The institutional review board at each center approved the
study protocol, and written informed consent was obtained
from all participants.
The MrOS Sweden cohort consists of three subcohorts from
three Swedish cities (n¼ 1005 in Malm€o, n¼ 1010 in Gothen-
burg, and n¼ 999 in Uppsala). Study subjects (men aged 69 to
81 years) were randomly selected using national population
registers, contacted, and asked to participate. To be eligible for
the study, the subjects had to be able towalk without assistance,
provide self-reported data, and sign an informed consent.(28)
The study was approved by the ethics committees at the
Universities of Gothenburg, Lund, and Uppsala. Informed
consent was obtained from all study participants.
TheMrOSHong Kong cohort includes 2000 Chinesemen aged
65 years or older who were recruited by advertisements placed
in housing estates and community centers for older people. All
subjects had to be community dwelling, able to walk without
assistance, and not have had bilateral hip replacement. Stratified
sampling was adopted to achieve approximately 33% of the
participants in each of the three age groups: 65 to 69, 70 to 74,
and 75 years.(29) The study protocol was approved by the
Chinese University of Hong Kong ethics committee, and written
informed consent was obtained from all participants.
Exclusion of participants with surgical or chemical castration
(as treatment for prostate cancer), androgen or antiandrogen
treatment and missing info on body mass index (BMI), prevalent
falls, or incident falls resulted in 1919 men in the US, 2495 in
Sweden, and 1469 in Hong Kong (combined 5883 men) who
were eligible for analyses.
Assessment of covariates
In the MrOS cohorts, we used a standardized questionnaire to
gather information about age, race/ethnicity, self-reported
prevalent diseases (Parkinson’s disease, angina, cancer, arthritis,
diabetes, stroke, myocardial infarction, and hypertension), and
use of central nervous system medication (benzodiazepines,
nonbenzodiazepine anticonvulsants, narcotic analgesics, selec-
tive serotonin reuptake inhibitors, trazodone, and tricyclic
antidepressants). Lifestyle factors such as falls (yes/no) during
the last 12 months preceding the baseline visit, alcohol
consumption, dizziness, use of walking aids (yes/no), and
mobility limitation (difficulties walking 2 to 3 blocks or up 10
stairs) were also obtained from self-reports. Types of medication
used regularly for the past month were coded during the clinical
visit. Alcohol use was expressed as three or more glasses of
alcohol-containing drinks per day, calculated from the reported
frequency and amount of alcohol use.
Physical performance was estimated by measurements of
hand-grip strength, a timed chair stands test, a 6-mwalking test,
and a 20-cm narrow walking test, as previously described.(30)
Briefly, grip strength was measured on a Jamar hand
dynamometer (Jackson, MI, USA). The maximum value (kilo-
grams) from two trials from both hands was analyzed. The time
to complete five chair stands (seconds) without using arms to
rise was recorded. The duration (seconds) of the 6-m walk at
usual pace wasmeasured. Two scored trials were performed and
the fastest walk was analyzed. The participants also walked the
same 6-m course within a 20-cm narrow path as a measure of
dynamic balance. Two scored trials with no more than two
deviations from the narrow path were performed and the fastest
narrow walk was analyzed. All tests were performed and
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registered by research nurses or trained research staff according
to standardized protocols.
Total body lean mass was assessed in MrOS Sweden at
baseline using the Lunar Prodigy DXA (GE Lunar Corp., Madison,
WI, USA) in theUppsala andMalm€o cohorts and theHologic QDR
4500/A-Delphi (Hologic, Inc., Bedford, MA, USA) in the Gothen-
burg cohort. In MrOS US and Hong Kong, lean mass was
measured using the Hologic QDR 4500/A-Delphi (Hologic, Inc.).
Standard equipment was used tomeasure height and weight.
BMI was calculated by dividing the weight in kg by the height in
meter squared.
Assessment of incident falls
Information on incident falls was collected by triannual mailed
questionnaires (MrOS US and Sweden) or telephone contacts
(MrOS Hong Kong). The participants were asked if they had
fallen in the previous 4 months. The mean number of incident
fall reports was 33.7 (range 1 to 47) forMrOSUS, 7.8 (range 1 to 9)
for MrOS Sweden, and 9.6 (range 1 to 12) for MrOS Hong Kong.
For the combined cohort of 5883 men with available sex steroid
measures, a total of 98,170 triannual fall reports were obtained
of which 12,998 reported at least one fall. Participants were
followed until the end of the study follow-up or death,
emigration (for Sweden), or discontinuation from the study.
Serum analyses
A total of 2047 men (1602 randomly sampled and all eligible
minorities with sufficient serum stored) from the MrOS US
cohort were selected for assessment of sex hormone levels by
gas chromatography (GC)-MS (Taylor Technology, Princeton, NJ,
USA).(31) For T, the limit of detection was 2.5 ng/dL, the intra-
assay coefficient of variation (CV) 2.5%, and the interassay CV
6.0%. For E2, the limit of detection was 0.625 pg/mL, the intra-
assay CV 6.4%, and the interassay CV 10.1%. SHBG was assayed
using an Immulite Analyzer with chemiluminescent substrate
(Diagnostic Products Corp., Los Angeles, CA, USA) on the same
samples previously thawed for the sex steroid measurements.
The intra-assay CV was 4.6% and the interassay CV 5.8%.
A validated GC-tandem MS system (Endoceutics, Quebec,
Canada)(32–34) was used to analyze serum T (limit of detection
0.05 ng/mL, intra-assay CV 2.9%, interassay CV 3.4%) and E2
(limit of detection 2.00 pg/mL, intra-assay CV 1.5%, interassay CV
2.7%) in the samples fromMrOS Sweden and Hong Kong. Serum
was also assayed for SHBG using an immunoradiometric assay
(Spectria, Orion Diagnostica, Espoo, Finland) with an intra-assay
CV of less than 5.5% and an interassay CV of less than 6.9%. A
random sample of 2645 and 1489 subjects in MrOS Sweden and
Hong Kong, respectively, had sufficient serum available for assay
of sex steroid hormones.
The majority of the MrOS US serum samples (97%) were
morning samples. More than half of the subjects in Sweden (69%)
had morning samples (drawn before 10:00 a.m.); the remaining
were drawn around noon. All Hong Kong samples were morning
samples. Accordingly, the various analyseswere adjusted for time
of serum sampling (morning sampling yes/no). Because the sex
hormones were measured with two different MS methods, a
cross-calibration of 50 samples was performed between the
Taylor and Endoceutics laboratories. This revealed strong
correlations between the E2 (r¼ 0.96) and T (r¼ 0.98) measure-
ments at both sites, with a small bias toward higher E2 values and
lower T values in the samples measured at the Taylor laboratory.
To compare sex steroid measurements from these two different
laboratories, the MrOS US Taylor sex steroid data were thus
adjusted as follows: adjusted E2¼ Taylor E2 – 1.9 pg/mL, adjusted
T¼ Taylor Tþ 16.8 ng/dL. BioT and BioE2 levels were calculated
using mass action equations described by S€odergård and
colleagues(35) and a fixed albumin concentration of 4.3 g/dL.
Sex steroid data (using a valid T measurement as reference)
were available in 2022 participants in the US, 2639 Swedishmen,
and 1489 Hong Kong men.
Statistical analyses
The associations between serum levels of sex steroids and SHBG
and incident falls were analyzed using generalized estimating
equations (GEEs) in which the outcome falls was modeled from
the repeated assessment of falls during each participant’s
follow-up. GEE models are an extension of generalized linear
models for analyzing longitudinal data(36,37) and are advanta-
geous in that they accommodate different lengths of follow-up
and, within a participant’s follow-up period, missing intervals.
GEE models were fitted using the geeglm function in the R
package geepack and a logit link.(38) The unit of analysis for
statistical modeling was the response from the triannual follow-
up questionnaires (fallen during the past 4 months yes/no).
Odds ratios (ORs) and 95% confidence intervals (CIs) were
estimated from the models and expressed as a 1-SD increase
(Z-score) in serum sex steroid or SHBG levels.
All estimates were adjusted for the following variables: age at
baseline, prevalent falls, race, morning sampling (yes/no), site,
and for the combined cohort, MrOS study cohort. A variable
related to the triannual questionnaire, more specifically the
number of the returned questionnaire or telephone contact
(report number), was also included in the models as we
previously described.(39)
Quadratic models were used to test for possible nonlinearity
in the association between serum total T or BioT and likelihood
of falls. We also used a restricted cubic spline approach for a
flexible nonlinear assessment of the OR in relation to total T or
BioT. The models were fitted using the gee function in the R
package gee(38) and the rcs function in the rms package.(40) The
number of knots was selected based on the smallest quasi-
likelihood based information criterion (QIC).(41) We tested fitting
3, 4, and 5 knots and found 3 knots to give the smallest QIC. In
these models, age at baseline, prevalent falls, race, morning
sampling (yes/no), report number, site, and MrOS study cohort
were used as covariates.
To evaluate whether the association between serum total T or
BioT and falls was confounded by poor physical performance,
further adjustments were made for physical performance
variables (grip strength, timed chair stand, walking speed, and
narrow walk), total body lean mass, and BMI.
The following baseline comorbidities were examined: alcohol
use, prevalent medical conditions (Parkinson’s disease, angina,
cancer, arthritis, diabetes, stroke, myocardial infarction, hyper-
tension), dizziness, use of walking aids, mobility limitations, and
use of central nervous system medication. All these comorbid-
ities were significantly associated with incident falls (statistical
significance was set at p< 0.05).
Results
Characteristics of the study subjects
The baseline characteristics of the study subjects in the
individual and merged MrOS cohorts are shown in Table 1
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and Supplemental Table S1. The mean age of the men in the
combined cohort (n¼ 5883) was 74.0 years. MrOS subjects in
Hong Kong had higher total T levels compared with the men in
the US and Sweden (Table 1). Incident falls were ascertained
triannually during a mean follow-up of 11.2 (US), 2.7 (Sweden),
and 3.8 years (Hong Kong). The mean number of missing fall
reports per participant and per year is higher in MrOS Sweden
(0.13) and MrOS Hong Kong (0.39) compared with MrOS US
(0.01). The incident fall rate (number of reports with a fall per
participant and per year) was highest in the US and lowest in
Hong Kong (Table 1). During an average follow-up time of 5.7
years, 50.7% of the men reported at least one fall. The incident
fall rates of the participants in the individual cohorts of the
current study (Table 1) are very similar to those in the
corresponding total cohorts (MrOS US total cohort 0.52, MrOS
Sweden total cohort 0.32, MrOS Hong Kong 0.12 reports with a
fall per participant per year). Likewise, the percentage of
participants with at least one fall during follow-up was also very
similar for the total cohorts (MrOS US total cohort 83.7, MrOS
Sweden total cohort 39.2, MrOS Hong Kong 29.4%) compared
with the cohorts in the current study. The overall percentage of
fallers in the merged total cohorts is higher than in the
combined cohorts in the current study (61.8% versus 50.7%)
because of a much larger number of participants in the total US
cohort compared with the current US cohort and the already
higher incident fall rate in MrOS US compared with MrOS
Sweden and Hong Kong.
Serum total T and BioT as risk factors for incident falls
Prevalent falls at baseline strongly predicted the risk of incident
falls in the combined set of cohorts (OR¼ 2.68, 95%CI 2.57–2.80)
and in the three cohorts separately (data not shown). In the
combined cohort of 5883men, both serum total T and BioTwere
associated with a greater likelihood of incident falls in basic GEE
models adjusted for age, prevalent falls, race, morning sample
(yes/no), report number, site, andMrOS study cohort (Table 2). In
contrast, serum levels of E2, BioE2, and SHBG were not
significantly associated with incident falls (Table 2). Quadratic
models indicated a nonlinear relationship between serum total T
or BioT and fall risk (p< 0.05). To further explore this apparent
nonlinear association, we performed restricted cubic spline
analyses. The resulting plots illustrated that the increased
likelihood of falls emergesmost prominently formenwith total T
(Fig. 1A) or BioT levels (Fig. 1B) in the lowest quartile. In addition,
we investigated the likelihood of falling in participants with
hypogonadism, defined as serum total T 300 ng/dL(42) or BioT
<163 ng/dL.(43,44) Both low total T (OR¼ 1.21, 95% CI 1.16–1.27)
and low BioT (OR¼ 1.27, 95% CI 1.21–1.33) were associated with
increased falls.
Serum total T and BioT as risk factors for incident falls
independently of physical performance, lean mass, and
comorbidities
To investigate whether the associations between serum total T
and BioT and incident falls were mediated by lean mass or
physical performance, we added physical performance
variables (grip strength, timed chair stand, walking speed,
and narrow walk) and total body lean mass to the basic
models. The inverse association between both total T and BioT
and the likelihood of falls persisted after adjustment for
individual physical performance variables (data not shown). In









Age (years) 74.0 (4.8) 73.3 (5.7) 75.5 (3.2) 72.5 (5.0)
Height (cm) 171.4 (8.1) 173.6 (7.1) 174.7 (6.4) 163.0 (5.7)
Weight (kg) 76.6 (14.6) 82.7 (13.5) 80.5 (12.0) 62.1 (9.4)
BMI (kg/m2) 25.9 (3.9) 27.4 (3.8) 26.3 (3.6) 23.4 (3.1)
Serum sex steroids
Total T (ng/dL) 470 (184) 426 (157) 457 (176) 548 (204)
BioT (ng/dL) 243 (81) 217 (63) 242 (86) 280 (79)
Total E2 (pg/mL) 22.0 (9.9) 20.9 (7.7) 21.2 (7.5) 24.6 (14.4)
BioE2 (pg/mL) 15.1 (7.0) 14.2 (5.0) 14.7 (5.4) 16.8 (10.4)
SHBG (nmol/L) 49.1 (20.9) 49.1 (19.7) 47.8 (22.1) 51.1 (20.3)
Prevalent falls (n, %) 1000 (17.0) 372 (19.4) 407 (16.3) 221 (15.0)
Incident falls
Follow-up time (years) 5.7 (4.6) 11.2 (4.3) 2.7 (0.6) 3.8 (0.7)
Participants with at least one incident fall (n, %) 2985 (50.7) 1578 (82.2) 963 (38.6) 444 (30.2)
Incident fall rate (number of reports with a fall/
participant/year)
0.33 (0.52) 0.50 (0.56) 0.31 (0.56) 0.12 (0.24)
BMI¼body mass index; T¼ testosterone; Bio¼bioavailable; E2¼ estradiol; SHBG¼ sex hormone-binding globulin.
Values are given as mean (SD) unless otherwise indicated.
Table 2. Serum Sex Steroids and the Likelihood of Falls
All cohorts (n¼ 5883)
Total T (per SD increase) 0.88 (0.86–0.91)
BioT (per SD increase) 0.86 (0.83–0.88)
Total E2 (per SD increase) 1.01 (0.98–1.03)
BioE2 (per SD increase) 1.02 (0.99–1.04)
SHBG (per SD increase) 0.98 (0.96–1.00)
T¼ testosterone; Bio¼bioavailable; E2¼ estradiol; SHBG¼ sex hor-
mone-binding globulin.
Odds ratios are given with 95% CIs within parentheses. All estimates
were adjusted for age at baseline, prevalent falls, race, morning sampling
(yes/no), report number, site, and MrOS study cohort.
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addition, the associations were only slightly attenuated after
simultaneous adjustment for all physical performance varia-
bles and lean mass (Table 3).
Similarly, the addition of multiple fall-related comorbidities
(dizziness, walking aids, mobility limitations, alcohol use, use of
central nervous system medication, and prevalent diseases
[Parkinson’s disease, angina, cancer, arthritis, diabetes, stroke,
myocardial infarction, and hypertension]) to the basic models
did not substantially change the associations between serum
total T or BioT and falls (Table 3). Also, the addition of narcotic
analgesics use alone to the model instead of combined central
nervous system medication use did not affect the associations
between total T (combined cohort: OR per SD increase¼ 0.94,
95% CI 0.91–0.96) or BioT (combined cohort: OR per SD
increase¼ 0.91, 95% CI 0.88–0.94) and incident falls. Compara-
ble results were obtained for total T and BioT when the basic
models were adjusted for physical performance variables, lean
mass, and comorbidities simultaneously (Table 3). Serum levels
of E2, BioE2, and SHBG were not significantly associated with
falls in any of the above multivariate models, confirming the
data from the basic models (data not shown).
The association between serum total T or BioT and falls
in relation to the duration of follow-up
We next evaluated the effect of the follow-up time on the
associations between baseline serum total T or BioT and the
likelihood of falls. The inverse associations between serum total
T or BioT and incident falls were already significant after 1 year of
follow-up (Table 4). Moreover, the results were essentially
unchanged after 2, 3, and even 16 years of follow-up. To reduce
the potential effect of subclinical or unrecognized disease, we
performed the analyses excluding the first year of follow-up. This
restriction did not affect the association between serum total T
(combined cohort: OR per SD increase¼ 0.88, 95% CI 0.86–0.90)
or BioT (combined cohort: OR per SD increase¼ 0.85, 95% CI
0.83–0.88) and incident falls.
The association between serum total T or BioT and falls
in the individual cohorts
Analyses in the individual cohorts showed that in MrOS US and
Sweden, serum total T and BioT associated inversely with
incident falls in basic models adjusted for age, prevalent falls,
race, morning sample (yes/no), report number, and site
(Supplemental Table S2). In contrast, the associations were
not significant in the MrOS Hong Kong cohort. Further
exploratory analyses were performed in the Asian men
participating in the MrOS US cohort (ie, not only Hong Kong
Chinese but also men from other parts of Asia) with an incident
fall rate of 0.33 reports with falls/participant/year. For these
Fig. 1. Smoothed plots of the likelihood of incident falls according to
serum total T and BioT concentrations. Odds ratios (ORs, solid line) and
95% confidence intervals (CIs, dashed lines) were estimated by restricted
cubic spline analyses using the median total testosterone (T, 447 ng/dL)
(Fig. 1A) or bioavailable testosterone (BioT, 236 ng/dL) (Fig. 1B)
concentration as reference values. Three knots positioned at the 25th,
50th, and 75th percentiles of the serum total T or BioT concentration
were used. The models were adjusted for age at baseline, prevalent falls,
race, morning sampling (yes/no), report number, site, and MrOS study
cohort. The cut-offs for the 25th and 75th percentiles are 346 and
569 ng/dL, respectively, for total T, and 190 and 292 ng/dL, respectively,
for BioT.
Table 3. The Effect of Physical Performance, Lean Mass and




Total T (per SD increase) 0.88 (0.86–0.91)
BioT (per SD increase) 0.86 (0.83–0.88)
Base modelþphysical performance
Total T (per SD increase) 0.94 (0.91–0.96)
BioT (per SD increase) 0.91 (0.89–0.94)
Base modelþ comorbidities
Total T (per SD increase) 0.94 (0.92–0.96)
BioT (per SD increase) 0.92 (0.89–0.94)
Base modelþphysical performanceþ comorbidities
Total T (per SD increase) 0.97 (0.94–1.00)
BioT (per SD increase) 0.94 (0.91–0.97)
T¼ testosterone; Bio¼bioavailable.
Odds ratios are given with 95% CIs within parentheses. All estimates
were adjusted for age at baseline, prevalent falls, race, morning sampling
(yes/no), report number, site, and MrOS study cohort. Physical
performance includes further adjustment for grip strength, timed chair
stand, walking speed, narrow walk, lean mass, and BMI (n¼ 5262 after
adjustment for physical performance and lean mass variables).
Comorbidities include prevalent diseases (Parkinson’s disease, angina,
cancer, arthritis, diabetes, stroke, myocardial infarction, and hyperten-
sion), dizziness, walking aids, mobility limitations, alcohol use, and use of
central nervous system medication (n¼ 5701 after adjustment for
comorbidities). The models with combined adjustment for physical
performance variables and comorbidities included 5105 participants.
p¼ 0.033.
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participants (n¼ 169), baseline serum total T (OR per SD
increase¼ 0.75, 95% CI 0.65–0.86) and BioT (OR per SD
increase¼ 0.66, 95% CI 0.58–0.75) were significant predictors
of incident falls in the basic models. Similar results were
obtained when the follow-up time of the Asian men in MrOS US
was limited to that of the MrOS Hong Kong cohort (total T: OR
per SD increase¼ 0.67, 95% CI 0.55–0.83; BioT: OR per SD
increase¼ 0.63, 95% CI 0.50–0.79).
Discussion
In this large, prospective study of older men, subjects with low
total T or BioT had an increased fall risk. The association between
both total T and BioT and falls was at least partly independent of
physical performance and lean mass and remained relatively
unchanged over time.
With aging, the serum levels of androgens inmen decline, and
these changes are related to the age-related occurrence of
sarcopenia, frailty, and physical disabilities.(4) Because the
reductions in muscle strength and physical performance in
turn increase the likelihood of falling, it is postulated that the
lower T levels in older men may contribute to the risk of falling.
The associations between serum T and falls have earlier been
prospectively investigated with contradictory results.(7,21) In the
US MrOS cohort, serum T levels were associated with falls,
whereas the association was not found to be present in LASA.
However, in both studies, serum sex steroid concentrationswere
assessed by radioimmunoassay, a technique known to have a
reduced specificity and accuracy, especially at lower concen-
trations.(22–25) In the present study, we evaluated the associa-
tions between serum sex steroids levels and SHBG and fall risk in
a larger number of men participating in the three international
MrOS cohorts, with serum E2 and T levels measured by the gold
standard MS. We show that both low total T and BioT levels, but
not E2, BioE2, or SHBG levels, were associated with an increased
likelihood of falls in the combined cohort of oldermen during an
average follow-up of 5.7 years. Further analyses showed that the
relation between total T or BioT and fall risk wasmost prominent
for those men with total T or BioT levels in the lowest quartile
(total T <346 ng/dL, BioT <190 ng/dL). Similarly, the likelihood
of falling was higher in hypogonadal men based on either low
total T or low BioT levels. These data, using state-of-the-art MS
for the assessment of serum sex steroids, confirm and extend a
previous report in the US MrOS cohort using immunoassay for
sex steroid measurement and with a shorter follow-up time.(21)
Adjustment for multiple fall-related comorbidities did not
materially change the association between total T or BioT and
fall risk. Also, in our study, the association between both baseline
serum total T and BioT and the likelihood of falls did not diminish
over time. The relation was already apparent after 1 year of
follow-up and persisted up to 16 years of follow-up (themaximal
follow-up time in MrOS US). In addition, the observed
associations are most likely not confounded by prevalent
diseases because results of models adjusting for comorbidity
were similar and exclusion of the first year of follow-up did not
alter the association between total T and BioT and falls.
The association of both total T and BioT with incident falls
persisted and was only slightly attenuated after adjustment for
physical performance and lean mass, similarly as previously
reported in the US MrOS cohort.(21) This suggests that T affects
the likelihood of falls at least partly independently of muscle
mass and physical performance. Other factors contributing to
fall risk are neuromuscular coordination and vision. Serum
androgen levels were found to be associated with balance
parameters. In the MINOS study, hypogonadism (total T
<257 ng/dL) was associated with impaired static and dynamic
balance.(20) Also, BioT was positively associated with balance in
healthymen.(45) In the present study, we adjusted for balance by
using our narrow walk performance test and results were only
partially attenuated. In addition, we adjusted for medications
affecting the central nervous system, dizziness, and alcohol use.
Analyses of the association between sex steroids and falls in
the individual MrOS cohorts revealed distinct results. In both
MrOS US and Sweden, serum total T and BioT were inversely
associated with incident falls, whereas the associations were not
significant in MrOS Hong Kong. The finding that total T and BioT
significantly predicted fall risk in the MrOS US Asian participants
(who not only originate from China but also from other Asian
countries) suggests that the absence of a significant association
between total T or BioT and falls in MrOS Hong Kong is not
owing to ethnic differences but rather to environmental factors.
Alternatively, this discrepancy can be explained by the
difference in fall rate or reporting frequency in the three
cohorts. The fall rate (number of fall reports per participant and
per year) in Hong Kong is much lower than in the US and
Sweden. The latter may, at least partly, be linked to the higher
serum T levels in the Hong Kongmen compared withmen in the
US and Sweden.(34) Also, the low fall rate and the lack of a
significant association between total T and incident falls in MrOS
Hong Kong may be linked to the fact that in this cohort fall data
were collected by telephone contact, whereas incident falls were
collected via questionnaires in the two other MrOS cohorts.
Finally, the reduced prevalence of fall-related comorbidities in
the MrOS Hong Kong cohort might also contribute to the lack of
a significant association between serum T and falls in MrOS
Hong Kong.
Our study has a number of strengths. It consists of the largest
fall data set in men to date with a substantial follow-up period.
Moreover, sex steroid levels are determined by the gold
standard MS method. The ability to statistically adjust for a
large number of fall-related covariates to limit cofounding is also
a strength. This study has, however, limitations. The fall events
are based on self-report, which may have resulted in recall bias.
The fact that the number of missing fall reports is higher in the
MrOS Hong Kong and MrOS Sweden cohorts compared with
MrOS US is also a limitation. Moreover, the results are based on
Table 4. The Association Between Serum Total T or BioT and
Falls in Relation to the Duration of Follow-up






0–1 year 0.90 (0.85–0.96) 0.87 (0.82–0.93)
0–2 years 0.93 (0.89–0.97) 0.90 (0.86–0.94)
0–3 years 0.92 (0.88–0.95) 0.89 (0.85–0.92)
0–16 years
(all data)
0.88 (0.86–0.91) 0.86 (0.83–0.88)
T¼ testosterone; Bio¼bioavailable.
Odds ratios are given with 95% CIs within parentheses (n¼ 5883 for
the combined cohort). All estimates were adjusted for age at baseline,
prevalent falls, race, morning sampling (yes/no), report number, site, and
MrOS study cohort.
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single serum sex steroid measurements and may thus
underestimate true associations. Other limitations include the
inclusion of some non-morning samples, which might have
contributed to increased variability, but this was adjusted for in
all the analyses by time of sampling. In addition, a main
limitation of the present study is that bioavailable sex steroid
levels were calculated and not, as preferable, directly mea-
sured.(46) Yet, results for total hormone levels as well as less
validated calculated bioavailable levels are shown because the
latter have been and are still used in epidemiological studies.
Finally, we have tried to adequately adjust for confounders in all
our analyses but cannot rule out residual confounding.
In summary, we show that low total T and BioT, but not low E2
or SHBG, are associated with increased falls in older men. These
data, using state-of-the-art MS for assessment of serum sex
steroids, confirm and extend previous findings in the US MrOS
cohort. Also, the effect of T on the likelihood of falling is
mediated, at least partly, by muscle mass and physical
performance. Both falls and bone strength parameters are
independent predictors of fracture risk in older men. With the
present data, we propose that low serum T influences fracture
risk via an increased risk of falls, whereas low E2 might increase
fracture risk mainly through reduced bone strength.
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